Ranibizumab is an anti-VEGF-A monoclonal antibody fragment that reduces the bioactivity of vitreous and prevents the development of PVR.
The National Eye Institute of NIH, Canadian Institute of Health Research, Department of Defense and Massachusetts Lions Foundation funded the study.
More Articles on Ophthalmology:
NovaBay Pharmaceuticals Begins Patient Trial of Pink-Eye Treatment
FDA Approves PROLENSA from Bausch + Lomb
LENSAR Laser System Earns FDA 510(k) Clearance
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
